Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

ination with Capecitabine in Patients with Advanced Breast Cancer.
  • Patricia Gomez, M.D., Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain
  • Abstract 1083, General Poster Session, Breast Cancer Track
  • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

"With more than 70 investigator and company sponsored studies being presented at ASCO, we look forward to continuing our work with investigators to understand how Nexavar may fit into other areas of the therapeutic landscape, particularly with respect to how biomarkers status may guide selection of therapy, which is a step toward personalized medicine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by other companies, international study groups, government agencies a
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... WriteResult, a premier provider of ePRO ... University’s School of Public Health and New Haven Farms ... 4 month-long project. The goal of the study was ... with free access to fresh produce and nutrition education ... like high blood pressure, diabetes and weight gain. Patients ...
(Date:3/25/2015)... -- Optimal Research, LLC has been nominated as a ... Clinical Site or Trial Network". This is ... as a nominee in this ViE award category at ... in 2014. The ViE awards were created to honor ... contributions of companies and individuals in the vaccine industry. ...
(Date:3/25/2015)... 2015 Accelovance, a therapeutically focused contract research ... Contract Research Organization" at the upcoming Vaccine Industry Excellence ... This is the eighth consecutive year Accelovance ... winning for "Best Contract Research Organization" in 2009, 2010, ... 2013. "We,re excited to be a finalist ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... organization is devoted to improving healthcare in rural South ... Africa for the welfare of its people, NEW YORK, ... USA LLP, has been named Chairman of the Board of,the American Friends ... Deloitte, to support the critical work of,the AFPT Board, Archbishop Desmond Tutu ...
... genes that confer risk of, common diseases is empowering individuals ... ... Nov. 16 deCODE genetics,(Nasdaq: DCGN ) today announced the launch ... at their own,genome. Through your subscription to deCODEme(TM), you can learn ...
... release is available in German . , ... simple methods for the production of tiny particles with ... regular patterns in two or three dimensions and at ... have countless applications in modern technology, from diagnostic systems ...
Cached Biology Technology:Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train 2deCODE Launches deCODEme(TM) 2deCODE Launches deCODEme(TM) 3deCODE Launches deCODEme(TM) 4Two-faced miniatures 2
(Date:3/17/2015)... SAN DIEGO , March 17, 2015 /PRNewswire/ ... and emotion analytics software, today announced general availability ... on-demand web service for the analysis of facial ... they experience advertising, media content, products and services. ... customer attention, engagement and sentiment - as derived ...
(Date:3/12/2015)... , March 12, 2015 IriTech, a ... a member of the Texas Instruments Design Network, announced ... has demonstrated its IriShield USB MK2120U device during ... facility for pension distribution. The iris ... to be marketed in India ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... just 60 years for humans to put many freshwater lakes ... recovery may take a thousand years under the best of ... the Proceedings of the National Academy of Sciences (PNAS), University ... study that showed that the buildup of phosphorus in soils ...
... before Europeans brought honey bees (Apis mellifera) to the Americas, ... stingless bees native to tropical forests. Now, colleagues from the ... the Smithsonian Tropical Research Institute (STRI) warn of the imminent ... of ongoing cultural change and habitat loss. , "In our ...
... for drug resistance in HIV-infected patients at the time ... life expectancy, according to an article in the Nov. ... , Resistance to antiretroviral therapy, even in patients ... However, genotype resistance testing, which involves looking for the ...
Cached Biology News:Study shows eutrophic lakes may not recover for a millennium 2Study shows eutrophic lakes may not recover for a millennium 3Mayan stingless bee keeping: Going, going, gone? 2Drug resistance testing in treatment-naive HIV patients is cost-effective 2
... protein assay reagents package is used for determining ... and detergents. The RC DC protein assay is ... for 500 standard assays: 250 ml RC reagent ... alkaline copper tartrate solution, 2 L dilute Folin ...
... modification that plays an important role ... inflammation, cell-to-cell adhesion, and cell signaling. ... based Glycoprotein Isolation Kits, Concanavalin A ... that allow isolation of glycoproteins from ...
... and PowerPac Basic power supply are used for ... Trans-Blot cell accommodates two 7.5 x 10 cm ... electrode assembly, Bio-Ice cooling unit, buffer tank, lid ... PowerPac basic power supply, 100-120 and 220-240 V, ...
... provides the sensitivity and versatility you expect ... photon counting with selected photomultipliers ensure superior ... Equipped with up to 2 reagent injectors ... gene assays as well as other luminescence ...
Biology Products: